NEWS

• Idenix Pharmaceuticals Announces Collaboration With Janssen To Initiate Phase II All-Oral Combination Studies Including IDX719, Simeprevir (TMC435) And TMC647055 For The Treatment Of Hepatitis C Virus (HCV)

  Idenix Pharmaceuticals, Inc. (Nasdaq:IDIX), a biopharmaceutical company engaged in the discovery and development of drugs for the treatment of human viral diseases, today announced a non-exclusive collaboration with Janssen Pharmaceuticals, Inc. for the clinical development of all-oral direct-acting antiviral (DAA) HCV combination therapies.

• Janssen Announces Collaboration With Vertex On Phase 2 Study To Investigate An All-Oral Regimen Of Simeprevir (TMC435) And VX-135 For Treatment Of Hepatitis C

  Janssen Pharmaceuticals, Inc. today announced that it has entered into a non-exclusive collaboration with Vertex Pharmaceuticals Incorporated to evaluate in a Phase 2 study the safety and efficacy of an all-oral regimen for the treatment of hepatitis C (HCV).

• Computer Model Successfully Predicts Drug Side Effects

  A new set of computer models has successfully predicted negative side effects in hundreds of current drugs, based on the similarity between their chemical structures and those molecules known to cause side effects, according to a paper appearing online this week in the journal Nature. By Kristen Bole

• FDA Approves Amyvid™ (Florbetapir F 18 Injection) For Use In Patients Being Evaluated For Alzheimer's Disease And Other Causes Of Cognitive Decline

  Eli Lilly and Company (NYSE: LLY) and Avid Radiopharmaceuticals, Inc., a wholly owned subsidiary of Lilly, today announced the U.S. Food and Drug Administration (FDA) approval of Amyvid™, a radioactive diagnostic agent indicated for brain imaging of beta-amyloid plaques in patients with cognitive impairment who are being evaluated for Alzheimer's Disease and other causes of cognitive decline.

• Absorption Systems' Innovation Rewarded With New U.S. Patent For CellPort Technologies Absorption Systems, a world leader in drug transporters, announces that a new U.S. patent issued on January 31^st, protecting intellectual property around its P-glycoprotein (P-gp) knockdown cell line within the company’s CellPort Technologies brand.
• Absorption Systems Expands In Vivo Drug Testing Capabilities Absorption Systems announces the latest in a series of milestones in the continuing expansion of its AAALAC-accredited and GLP-compliant facility in San Diego, CA.
• Absorption Systems Initiates Collaboration With Academic Researchers To Develop Improved In Vitro Pharmacokinetic Predictions

  In a collaborative effort, Absorption Systems is working with Drs. Ken Korzekwa and Swati Nagar of Temple University and Dr. Jeff Jones of Washington State University to develop technologies to improve the predictive power of certain in vitro-in vivo correlations (IVIVCs).

• Absorption Systems Boosts Ophthalmic Drug Testing Absorption Systems recently announced that, as part of the continuing expansion of capabilities at its San Diego, CA facility, the company has hired Glen Gum, M.S., Ph.D. as Associate Director of Preclinical Studies.
• Cytokinetics Announces Phase I And Phase IIa Clinical Trial Results For Omecamtiv Mecarbil Published In The Journal Lancet Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of results from two clinical trials of omecamtiv mecarbil, a novel cardiac myosin activator, in the August 20, 2011 issue of the journal Lancet.
• Spaulding Clinical Announces Strategic Partnership With Clinigene International, India For Providing Comprehensive Early Clinical Solutions To Pharmaceutical And Biotech Clients Clinigene International Limited, an India-based Central and Bioanalytical Laboratory and Phase I-IV Clinical Research Organization, and Spaulding Clinical Research, LLC, US-based leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a strategic partnership agreement.
• Spaulding Clinical Announces New Joint Partnership For Global Studies With Eurofins Optimed Clinical Research Eurofins Optimed Clinical Research, an experienced European clinical research service provider and Spaulding Clinical Research, LLC., US-based, leading-edge Clinical Pharmacology, Cardiac Core Lab, and Medical Device Manufacturer, announce a joint partnership agreement.